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Abstract
Vaccines based on recombinant proteins avoid toxicity and anti-vector immunity associated with
live vaccine (e.g., viral) vectors, but their immunogenicity is poor, particularly for CD8+ T-cell
(CD8T) responses. Synthetic particles carrying antigens and adjuvant molecules have been
developed to enhance subunit vaccines, but in general these materials have failed to elicit CD8T
responses comparable to live vectors in preclinical animal models. Here, we describe interbilayer-
crosslinked multilamellar vesicles (ICMVs) formed by crosslinking headgroups of adjacent lipid
bilayers within multilamellar vesicles. ICMVs stably entrapped protein antigens in the vesicle core
and lipid-based immunostimulatory molecules in the vesicle walls under extracellular conditions,
but exhibited rapid release in the presence of endolysosomal lipases. We found that these antigen/
adjuvant-carrying ICMVs form an extremely potent whole-protein vaccine, eliciting endogenous
T-cell and antibody responses comparable to the strongest vaccine vectors. These materials should
enable a range of subunit vaccines and provide new possibilities for protein therapeutic delivery.
Currently licensed vaccine adjuvants (e.g., aluminum hydroxide and the oil-in-water
emulsion MF59) promote immunity by primarily eliciting humoral immune responses,
without stimulating cellular immunity1,2. As strong CD8+ T cell (CD8T) responses may be
required for vaccines against cancer or intracellular pathogens such as HIV, malaria, and
hepatitis C, there is great interest in technologies to promote concerted humoral and cellular
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immune responses3,4. To this end, engineered live vaccine vectors such as non-replicating
recombinant viruses have been developed5–7, which can induce both robust antibody
responses and massive expansion of functional antigen-specific CD8+ T-cells in murine
models. However, safety concerns with live vectors and anti-vector immunity can
complicate live vector vaccine design7. Pre-existing vector-specific immune responses have
reduced the immunogenicity of live vector-based vaccines in clinical trials8, and the
immune response raised against live vectors following a priming immunization can render
booster immunizations using the same vector problematic7.
In contrast, non-living synthetic vaccines delivering defined antigens can be rationally
designed to avoid anti-vector immunity9. Such “subunit” vaccines are composed of one or a
few selected recombinant proteins or polysaccharides normally present in the structure of
the target pathogen. However, subunit vaccines elicit poor or non-existent CD8T responses,
due to the low efficiency of cross-presentation (the uptake and processing of extracellular
antigen by immune cells for presentation on class I MHC molecules to naive CD8+ T-
cells)10. To promote cross-presentation, synthetic particles loaded with protein antigens and
defined immunostimulatory molecules have been used11–17, mimicking in a reductionist
fashion the cues provided to the immune system during infection by pathogens. Liposomes
are particularly attractive materials for this application, due to their low toxicity and
immunogenicity, track record of safety in clinical use, ease of preparation, and proven
manufacturability at commercial scales18,19. Lipid vesicles in the form of unilamellar,
multilamellar, or polymerized vesicles have been tested as vaccine delivery materials, with
some success19–23. Antigens entrapped in lipid vesicles are cross-presented in
vivo19,24,25, and liposomal protein vaccines have been shown to elicit protective T-cell-
mediated anti-microbial and anti-tumor immune responses in small-animal models23,26,27.
However, for diseases such as HIV and cancer, it is currently believed that extremely potent
T-cell responses (in concert with humoral immunity) will be required to control the virus/
tumors, and therefore, more potent T-cell vaccines are still sought3,4.
A potential factor influencing the potency of lipid vesicles in vaccine delivery is their
limited stability in the presence of serum components. For liposomal cargos that can be
processed at high temperature or loaded by diffusion through pre-formed vesicle
membranes, enhanced vesicle stability can be achieved by using high-Tm lipids, especially
when combined with cholesterol and/or PEGylation28. Uni-and multi-lamellar vesicles have
also been stabilized by polymerizing reactive headgroups at the surface of bilayers29,
polymerizing reactive groups in phosholipid acyl tails20,29, or polymerizing hydrophobic
monomers adsorbed into the hydrophobic interior of membranes30. Common to each of
these approaches is the concept of polymerizing components in the plane of the bilayer.
However, finding polymerization chemistries that can be carried out in mild conditions
compatible with vaccine antigens is challenging20.
Here we describe a new class of lipid drug carriers, interbilayer-crosslinked multilamellar
vesicles (ICMVs), formed by stabilizing multilamellar vesicles with short covalent
crosslinks linking lipid headgroups across the opposing faces of adjacent tightly-stacked
bilayers within the vesicle walls. ICMVs encapsulated and stably retained high levels of
proteins, releasing entrapped cargo very slowly when exposed to serum (over 30 days)
compared to simple liposomes or multilamellar vesicles (MLVs) of the same lipid
composition. However, these vesicles were quickly degraded in the presence of lipases
normally found at high levels within intracellular compartments31. Using this novel vesicle
structure to co-entrap high levels of a model protein antigen (ovalbumin, OVA) and a lipid-
like immunostimulatory ligand (monophosphoryl lipid A, MPLA), we carried out
immunization studies in mice and found that ICMVs elicited robust antibody titers ~1000-
fold greater than simple liposomes and ~10-fold greater than MLVs of identical lipid
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compositions. Unlike live vectors that are often only effective for a single injection
administered to a vector-naïve individual7, these synthetic vesicles triggered steadily
increasing humoral and CD8+ T-cell responses following repeated administrations, with
antigen-specific T-cells expanding to a peak of nearly 30% of the total CD8+ T-cells in
blood following a prime and two booster immunizations. These new materials may thus
open the door to subunit vaccines that are both safe and highly effective for generating both
humoral and cellular immunity.
We introduced covalent crosslinks between functionalized lipid headgroups of adjacent,
apposed bilayers within preformed MLVs to form ICMVs (Fig. 1a): In a typical synthesis,
dried phospholipid films containing DOPC, anionic DOPG, and the anionic maleimide-
headgroup lipid MPB in a 4:1:5 molar ratio were hydrated and sonicated to form simple
liposomes (step (i)). Divalent cations (e.g., Mg2+) were added to the liposomes to induce
vesicle fusion and the formation of MLVs as reported previously32 (step (ii)). To introduce
crosslinks between adjacent bilayers in the MLVs, dithiothreitol (DTT) was then added to
the vesicle suspension to act as a membrane-permeable crosslinker, forming a covalent
linkage between maleimide headgroups of apposed membranes brought into proximity by
the cation salt bridges formed between vesicle layers (step (iii)). PEGylation is a well-
known strategy to increase the serum stability and blood circulation half-life of lipid
vesicles18. Thus as a final step, the vesicles were washed and residual maleimide groups
exposed on the external surfaces of the particles were capped with thiol-terminated PEG
(step (iv)).
The diameter/polydispersity of the particles will determine the cell types capable of
internalizing these particles33, while the number of bilayers comprising the vesicle walls
would be expected to impact the stability of the vesicles and their ability to retain/slowly
release cargos in the presence of serum. To evaluate these properties and better understand
the process of ICMV formation, we characterized the products at each step of the synthesis:
The initial liposomes formed by sonication (step (i)) had hydrodynamic diameters of ~190
nm, and the size increased slightly to ~ 240 nm following Mg2+-mediated vesicle fusion
(step (ii)) and subsequent DTT “stapling” of the bilayers (step (iii), Table 1). The resulting
ICMVs showed a monomodal, relatively narrow size distribution (comparable to common
lipid vesicle or polymer nanoparticle preparations12,21), and there was no evidence for
gross aggregation of particles during the crosslinking step from dynamic light scattering
(DLS) or cryoelectron microscopy (Fig. 1a, b, and Table 1). Addition of thiol-terminated
PEG to DTT-treated vesicles quenched remaining detectable maleimide groups on the
surfaces of MLVs and introduced PEG chains on ~2 mol% of the surface-exposed lipids of
ICMVs without significantly altering particle diameters (Supplementary Fig. S1a, b, and
Table 1). PEGylated ICMVs stored at 4°C or 37°C in PBS remained stable over 7 days, and
they were amenable to lyophilization with 3% sucrose added as an excipient34, highlighting
their compatibility with long-term storage conditions (Table 1 and data not shown). We
imaged the initial liposomes, Mg2+-fused MLVs, and the final ICMVs by cryoelectron
microscopy (Fig. 1a), and saw that crosslinking with DTT led to the formation of vesicles
with thick multilamellar walls composed of tightly stacked bilayers resolved as ~4–5 nm
electron-dense striations. The median number of bilayers per particle was 4.4 (interquartile
range [IQR], 3.3–6.9), and the median particle radius to lipid wall thickness ratio was 3.8
(IQR, 2.4–6.8) (Fig. 1c, d). Interestingly, the majority of ICMVs had vesicle walls
composed of concentric bilayers, although a few examples of ICMVs with surface defects in
the form of incomplete external lipid layers could also be found (Supplementary Fig. S2).
Consistent with the increased lamellarity of the vesicles following cation-mediated fusion
and DTT crosslinking observed by electron microscopy imaging, the fraction of lipids
exposed on the external surfaces of the vesicles decreased in steps (ii) and (iii) of the
synthesis, as measured by a bulk dye-quenching lamellarity assay35 (Table 1). Chemical
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evidence for crosslinking between the maleimide-lipids following DTT treatment was found
in thin-layer chromatography and MALDI-TOF measurements on ICMVs (Supplementary
Fig. S3 and data not shown). Importantly, both the particle size and individual lamellarity
distributions were monomodal, with less than 3 % contaminating unilamellar vesicles and no
large aggregates, which could skew the functional properties (e.g., protein release) of the
particles. The ICMVs have a size that should be avidly taken up by monocytes and dendritic
cells36, and a crosslinked multilamellar wall structure that will stabilize protein entrapment
compared to traditional unilamellar or multilamellar liposomes.
Analysis of the conditions required to form stable vesicles provided insight into the
mechanisms of ICMV formation. Following interbilayer-crosslinking, ICMVs could be
collected by centrifuging at 14,000 × g for 4 min (“low-speed conditions”), whereas simple
liposomes or MLVs of identical lipid composition required ultracentrifugation to pellet.
Using the mass of particles collected by low-speed centrifugation as a surrogate measure of
crosslinked vesicle yield, we found that both divalent cation-mediated fusion (Fig. 1a step
(ii), either Mg2+ or Ca2+) and DTT treatment (step (iii)) were required for ICMV formation
(Table 2; entries 1–3). Precursor vesicles treated with either Mg2+ or DTT alone even at 10X
molar excess relative to maleimide groups did not generate significant yields of particles
(Table 2, entries 4–6). In addition, at least 25 mol% MPB was required to form ICMVs
(Table 1, entries 1, 7–9); the high level of reactive headgroups required for substantial
ICMV yield may reflect competition between intra- (between headgroups on the same
bilayer) and inter-bilayer crosslink formation. DTT could be replaced with DPDPB, another
membrane-permeable dithiol, but not with 2 kDa PEG-dithiol (Supplementary Fig. S4 and
Table 2 entries 10, 11). ICMVs could also be formed using only DOPC and MPB lipids, or
using cationic DOTAP in place of DOPG (data not shown). As an alternative method to
form ICMVs, maleimide-dithiol crosslinking could be replaced with bio-orthogonal click
chemistry, employing alkyne-terminated lipids for vesicle formation and diazides for
crosslinking37,38 (Supplementary Fig. S5). Thus, interbilayer-crosslinking for the formation
of stabilized vesicles is a general strategy that can be adapted to other lipid/crosslinker
chemistries. Based on their high synthetic yield and colloidal stability, we chose to focus on
PEGylated ICMVs with a lipid composition of DOPC:DOPG:MPB in a 4:1:5 molar ratio for
further testing as protein/vaccine delivery vehicles.
To test the suitability of ICMVs for protein delivery, we examined the entrapment of several
globular proteins: SIV-gag, an HIV vaccine antigen; FLT-3L, a therapeutic cytokine; and
ovalbumin (OVA), a model vaccine antigen. Protein encapsulation was achieved by
rehydrating dried lipids with protein solutions in step (i) of the synthesis (Fig. 1a). The
amount of encapsulated protein increased at each step of the ICMV preparation (Fig. 2a),
which may reflect additional protein entrapment occurring as vesicle fusion occurs in both
steps (ii) and (iii). Protein entrapment in ICMVs was not mediated by conjugation of thiols
on the cargo proteins with the maleimide-functionalized lipid vesicles, as OVA pre-reduced
with TCEP and treated with ethyl-maleimide to block all thiol groups on the protein was
encapsulated in ICMVs at levels similar to unmodified protein (76.1 ± 6.3% vs. 83.3 ± 8.4
% for capped-thiol- vs. unmodified OVA; p = 0.17). We also confirmed that disulfide
linkages in model protein cargos were not reduced by the DTT crosslinker during the vesicle
formation process and that ICMV encapsulation did not trigger protein aggregation
(Supplementary Fig. S6). To directly compare the efficiency and quantity of protein loading
achieved with ICMVs to two of the most common types of drug delivery vehicles39–41, we
compared encapsulation of OVA in liposomes, PLGA nanoparticles, and ICMVs: Using a
model stable lipid composition comprised of phosphocholine, PEG-lipid, and cholesterol42,
we formed DRVs as one of the most efficient aqueous entrapment approaches for
liposomes43, and prepared OVA-loaded PLGA particles using a double-emulsion solvent-
evaporation process44. ICMVs exhibited superior encapsulation efficiency (~75 %)
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compared to either DRVs or PLGA particles (2-, and 4-fold increases, respectively; Fig. 2b),
and the amount of OVA encapsulated per total particle mass (~325 µg OVA per mg of
particles) was increased in ICMVs by 1.8-, and 9-fold compared to DRVs or PLGA
particles, respectively (Fig. 2c). Thus, ICMVs appear to be effective for encapsulating a
variety of globular proteins, and, at least for the model antigen OVA, ICMVs loaded protein
more efficiently than common alternative protein carriers.
We next determined whether interbilayer crosslinking enabled lipid vesicles to retain
biodegradability while increasing protein retention in the presence of serum. OVA was
loaded into PEGylated liposomes, Mg2+-fused MLVs, or ICMVs all with the same lipid
composition, and the kinetics of protein release at 37°C in media containing 10% fetal calf
serum were quantified. Unilamellar liposomes quickly released their entire payload of
entrapped OVA within ~2 days, while multilamellar Mg2+-fused MLVs released ~50% of
their entrapped cargo over the same time period (Fig. 2d). However, ICMVs showed a
significantly enhanced retention of protein, releasing only ~25% of their cargo by one week,
and ~90% after 30 days (Fig. 2d). Notably, ICMVs also released protein significantly more
slowly than unilamellar liposomes stabilized by the inclusion of cholesterol42 (Fig. 2d). The
crosslinked vesicles also retained ~95% of their entrapped protein when stored in PBS at
4°C for over 30 days (Fig. 2e). We also examined protein release from ICMVs in conditions
modeling intracellular compartments: vesicles incubated in reducing or acidic conditions for
1 day at 37°C retained > 95% of entrapped OVA, whereas incubation with phospholipase A
led to release of > 90% OVA and rapid vesicle degradation (Fig. 2e). Thus, ICMVs exhibit
enhanced stability in the presence of serum compared to traditional liposomal formulations,
but rapidly break down in the presence of enzymes that are present within intracellular
endolysosomal compartments31, providing a mechanism for triggered intracellular release
of cargo following internalization by cells. Although some protein degradation within
vesicles might be possible upon administration in vivo prior to internalization by cells,
critical uptake and processing of antigen will occur in the first few days after immunization
in vaccine delivery45, when such degradation processes should be minimal.
We hypothesized that the unique structure of ICMVs, with efficient retention of
encapsulated protein antigens in the extracellular environment but rapid release in
endosomes/lysosomes, would provide enhanced vaccine responses. To generate vaccine
ICMVs, we prepared vesicles carrying the model antigen OVA (OVA-ICMVs) and mixed
these vesicles with the molecular adjuvant monophosphoryl lipid A (MPLA). MPLA is an
FDA-approved agonist for Toll-like receptor (TLR) 4 expressed by dendritic cells, B-cells,
and innate immune cells, and potently amplifies vaccine responses1,46. Antigen-loaded
ICMVs mixed with MPLA promoted upregulation of costimulatory molecules on splenic
and bone-marrow dendritic cells (DCs) in vitro, compared to DCs pulsed with ICMVs
without MPLA (Fig. 3a and Supplementary Fig. S7). DCs pulsed with ICMVs cross-
presented peptides derived from OVA with greatly enhanced efficiency compared to those
pulsed with soluble OVA (with or without added MPLA), as determined by staining DCs
with the 25-D1.16 mAb that recognizes the SIINFEKL peptide (OVA257–264) complexed
with MHC class I H-2Kb molecules (p < 0.001, compared to soluble OVA or ICMVs-loaded
with irrelevant antigen [vivax malaria protein, VMP], Fig. 3b). Splenic DCs incubated with
OVA-ICMVs + MPLA triggered robust proliferation of OVA-specific naïve OT-1 CD8+ T-
cells in vitro, as assessed by a carboxyfluorescein succinimidyl ester (CFSE) dilution assay.
In contrast, weak T-cell responses were detected when DCs were pulsed with equivalent
doses of soluble OVA and MPLA, empty ICMVs, or VMP-ICMVs, indicating the
specificity of the T-cell responses elicited by ICMVs (Fig. 3c). These results suggest that
addition of MPLA allows equivalent DC activation by ICMVs or soluble OVA, but ICMVs
trigger enhanced cross-presentation of the antigen, as expected for particulate antigen
delivery.
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To determine the influence of vesicle structure on the immune response in vivo, we
vaccinated C57Bl/6 mice with equivalent doses of OVA, MPLA, and lipids (10 µg, 0.1 µg,
and 142 µg, respectively) in the form of PEGylated unilamellar liposomes, MLVs, or
ICMVs. Seven days after immunization, we assessed the strength of the endogenous CD8+
T-cell response by analyzing the frequency of OVA peptide-MHC tetramer+ (antigen-
specific) CD8+ T-cells among peripheral blood mononuclear cells (PBMCs) by flow
cytometry, and found a trend toward increasing T-cell responses in the order soluble OVA <
liposomes < Mg2+-fused MLVs < ICMVs (Fig. 4a). At 3 weeks post-immunization, Mg2+-
fused MLVs elicited ~100-fold greater OVA-specific IgG titers in the sera of the animals
compared to soluble OVA or unilamellar liposomes. However, ICMV immunization
generated a substantially stronger humoral response, ~1000-fold and ~10-fold greater than
the soluble OVA (p < 0.01) and non-crosslinked MLV immunizations (p < 0.05),
respectively (Fig. 4b). Thus, the stabilized structure of ICMVs promoted both T-cell and
antibody responses. Enhanced T-cell and antibody responses to immunization with ICMVs
compared to other formulations, could be attributed to improved antigen delivery to antigen-
presenting cells (APCs), enhanced activation of DCs, enhanced antigen cross-presentation
(as seen in vitro), or a combination of these factors. To distinguish between these
possibilities, mice were immunized with fluorophore-conjugated OVA mixed with MPLA as
a soluble, liposomal, or ICMV formulation, and the draining inguinal lymph node cells that
internalized OVA were assessed on day 2. OVA delivered by ICMVs was readily detected
in total DCs, macrophages, and plasmacytoid (CD11c+B220+) DCs in the draining lymph
nodes (dLNs), while soluble and liposomal formulations showed fluorescence barely above
background (p < 0.01, Fig. 4c, d). Repeating this analysis with unlabeled OVA, we found
that administration of OVA-ICMVs with MPLA triggered a minor enhancement of co-
stimulatory marker and MHC-II expression among DCs in dLNs compared to soluble or
liposomal OVA + MPLA (Fig. 4e and Supplementary Fig. S8). However, using the 25-
D1.16 antibody to detect OVA peptide presentation, we readily detected OVA peptide-MHC
complexes on DCs in the dLNs following ICMV immunization, whereas soluble OVA or
liposomal OVA injections did not give staining above the expected background cross-
reactivity of 25-D1.16 with self-peptide MHC complexes47 (Fig. 4f). All together, these
results suggest that improved retention of entrapped antigen in the crosslinked multilamellar
structures of ICMVs leads to enhanced antigen delivery to APCs, followed by enhanced
cross-presentation.
The multilamellar structure of ICMVs offers the opportunity to sequester not only protein
antigen (in the aqueous core) but also lipophilic molecules (in the vesicle walls). We thus
tested whether embedding MPLA throughout the walls of the ICMVs would impact the
immune response in vivo, by allowing better retention of MPLA together with antigen in the
vesicles. The TLR agonist was incorporated throughout the vesicle layers by co-dissolving
MPLA with the other lipids in the first step of the synthesis (int-MPLA ICMVs), and we
compared these vesicles to ICMVs carrying the same amount of MPLA incorporated only
on the vesicle surfaces via a post-insertion approach (ext-MPLA ICMVs, Fig. 5a,
Supplementary Methods). Mice were immunized s.c. with OVA (10 µg) and MPLA (0.1 µg
or 1.0 µg) in ICMVs or soluble form, and boosted on d21 and d35 with the same
formulations. As shown in Fig. 5b, immunizations using the low dose of MPLA led to a
barely detectable antibody response against soluble OVA even following two boosts, while
both int-MPLA and ext-MPLA ICMVs elicited strong anti-OVA serum IgG titers by d56.
An IgG response to soluble OVA could be obtained using 10-fold more MPLA, but int-
MPLA ICMVs with 1.0 µg MPLA elicited higher titers than soluble protein (~13-fold
greater on d56). On the other hand, we did not observe any significant level of antibodies
directed against lipid components of ICMVs throughout these immunization studies (data
not shown).
Moon et al. Page 6
Nat Mater. Author manuscript; available in PMC 2011 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Embedding MPLA in the multilayers of ICMVs had a more striking effect on the CD8+ T-
cell response to vaccination. Soluble OVA mixed with 0.1 µg MPLA elicited barely
detectable antigen-specific T-cell expansion as assessed by tetramer staining on PBMCs;
ext-MPLA ICMV delivery led to a 2.5-fold increased tetramer+ T-cell population by d41
(Fig. 5c, p < 0.05). Adding 10-fold more MPLA allowed soluble OVA immunizations to
eventually reach T-cell responses equivalent to ext-MPLA ICMVs following boosting. By
contrast, immunization with int-MPLA ICMVs elicited dramatically stronger CD8+ T-cell
responses that continued to expand following each boost, achieving a peak 28% tetramer+ T-
cells in the CD8+ T-cell population by d41 (5-fold greater than ext-MPLA ICMVs (p < 0.05)
and 14-fold greater than soluble OVA+MPLA (p < 0.01) Fig. 5c). Notably, int-MPLA
ICMVs elicited overall a significantly higher frequency of tetramer+CD44+CD62L+ cells (p
< 0.01, Fig. 5d), a phenotype for central memory T-cells known to confer long-lived
protection against pathogens and tumors48. Antigen specific T-cells elicited by int-MPLA
ICMVs persisted even after one month after the final boosting, with ~11% tetramer+ T-cells
among CD8+ T-cells (3-fold and 8-fold greater than ext-MPLA ICMVs and soluble OVA
+MPLA, respectively, p < 0.05 for both, Fig. 5c). To test the functionality of T-cells
expanded by these immunizations, we assessed the ability of CD8+ T-cells from peripheral
blood to produce interferon-γ (IFN-γ) upon restimulation ex vivo on d49. Mice immunized
with int-MPLA ICMVs had much higher levels of IFN-γ-competent T-cells than mice
receiving ext-MPLA ICMVs or soluble OVA-immunizations (p < 0.05, Fig. 5e). To our
knowledge, in terms of the degree of antigen-specific T-cell expansion, persistence of
memory cells, and IFN-γ functionality, this is one of the strongest endogenous T-cell
responses ever reported for a protein vaccine, comparable to strong live vectors such as
recombinant viruses5,6. Notably, this is achieved via “homologous” boosting, repeated
immunization with the same particle formulation, a strategy that cannot be used with many
live vectors due to immune responses raised against the pathogen-based delivery vector
itself7.
These studies demonstrate the synthesis of a new class of submicron particle reagents based
on crosslinked multilamellar lipid vesicles, which combine a number of attractive features
for biomedical applications; the particle synthesis does not require exposure of protein
cargos to organic solvents, the lipid basis of the particles makes them inherently
biodegradable to metabolizable byproducts, the phospholipid shell enables modular
entrapment of both lipophilic and hydrophilic cargos, proteins are encapsulated at very high
levels per mass of particles, and protein release from the particles can be sustained over very
long durations. These results suggest ICMVs may be a very effective vehicle for delivering
biomacromolecules, and in particular, for vaccine applications. The ability to achieve such
strong combined T-cell and antibody responses using a synthetic particle vaccine could open
up new possibilities for vaccination in the setting of infectious disease and cancer.
MATERIALS AND METHODS
Synthesis of ICMVs
1.26 µmol of lipids in chloroform (typical lipid composition: DOPC(1,2-Dioleoyl-sn-
Glycero-3-Phosphocholine):DOPG(1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-
glycerol)): MPB (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-
maleimidophenyl) butyramide) = 4:1:5 molar ratio, all lipids from Avanti Polar Lipids,
Alabaster, AL) were dispensed to glass vials, and the organic solvents were evaporated
under vacuum overnight to prepare dried thin lipid films. The lipid films were rehydrated in
10 mM bis-tris propane at pH 7.0 with cargo proteins for 1 hr with rigorous vortexing every
10 min, and then sonicated in alternating power cycles of 6 watts and 3 watts in 30s intervals
for 5 min on ice (Misonix Microson XL probe tip sonicator, Farmingdale, NY). The
liposomes formed in this first step were induced to undergo fusion by addition of divalent
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cations such as Mg2+ and Ca2+ at a final concentration of 10 mM. The resulting MLVs were
incubated with 1.5 mM DTT (maleimide:DTT molar ratio of 2:1) for 1 hr at 37°C to
conjugate opposing bilayers of maleimide-functionalized lipids and form crosslinked
ICMVs; the resulting vesicles were recovered by centrifugation at 14,000 ×g for 4 min, and
washed twice with deionized water. For PEGylation, the particles were incubated with 2
kDa PEG-thiol (Laysan Bio, Arab, AL) in a 1.5-fold molar excess of PEG-SH to maleimide
groups for 1 hr at 37°C. The resulting particles were centrifuged and washed 3X with
deionized water. The final products were either stored in PBS at 4°C or lyophilized in the
presence of 3% sucrose as a cryoprotectant and stored at −20°C. For some assays, simple
liposomes or Mg-fused MLVs were harvested prior to crosslinking with ultracentrifugation
at 115 k × g using an Optima ultracentrifuge for 6 hrs (Beckman Coulter).
In vitro protein loading and drug release
For encapsulation studies, ovalbumin (OVA, Worthington, Lakewood, NJ), SIV-gag
(Advanced Bioscience Laboratories, Kensington, MD), and FLT-3L (Peprotech, Rocky Hill,
NJ) were labeled with Alexa-Fluor 555 (Invitrogen, Carlsbad, CA) for direct fluorometric
quantification of the amount of protein entrapped. OVA was also encapsulated in DRVs and
PLGA nanoparticles as described previously43,44. In some experiments, ICMVs were
loaded with a recombinant vivax malaria protein (VMP) as an irrelevant antigen control49
(provided by Dr. Anjali Yadava, Walter Reed Army Institute of Research). Capped-thiol
OVA was prepared by incubating 1 mg of OVA with 1.5 mM TCEP for 1 hr at RT, followed
by incubation with 1.5 mM ethyl-maleimide (Pierce, Rockford, IL) at 37 °C for 1hr. The
extent of thiol protection was > 95% as assessed with Ellman’s assay50. Release of OVA
labeled with Alexa-Fluor 555 from lipid vesicles was quantified in RPMI media
supplemented with 10% fetal calf serum at 37°C using dialysis membranes with MW cutoff
of 100 kDa. At regular intervals, the releasing media were removed for quantification of
fluorescence, and an equal volume of fresh media were replaced for continued monitoring of
drug release. Residual OVA remaining at the end of the time-course was determined by lipid
extraction of vesicles with 1% Triton X-100 treatment and measuring released protein by
fluorescence spectrophotometry. OVA release assays were also performed in Hank’s
buffered saline solution supplemented with 500 ng/ml of phospholipase A (Sigma, St. Louis,
MO). To examine stability of encapsulated cargo molecules, monoclonal rat IgG
encapsulated in ICMVs was retrieved with 1% triton X-100 treatment and analyzed with
SDS-PAGE under non-reducing conditions with silver staining (Pierce).
Vaccination study with ICMVs
Groups of C57Bl/6 mice (Jackson Laboratories) were immunized s.c. in the tail base with
indicated doses of OVA (with or without TLR agonists, MPLA). Frequencies of OVA-
specific CD8+ T-cells and their phenotypes elicited by immunization were determined by
flow cytometry analysis of PBMCs at selected time points following staining with DAPI (to
discriminate live/dead cells), anti-CD8α, anti-CD44, anti-CD62L, and SIINFEKL/H-2Kb
peptide-MHC tetramers (Becton Dickinson). To assess functionality of primed CD8+ T-
cells, PBMCs were stimulated ex vivo with 1 µM OVA-peptide SIINFEKL for 6 hrs with
GolgiPlug (Becton Dickinson), fixed, permeabilized, stained with anti- IFN-γ and CD8α,
and analyzed by flow cytometry. Anti-OVA IgG titers, defined as the dilution of sera at
which 450 nm OD reading is 0.5, were determined by ELISA analysis of sera from
immunized mice. Animals were cared for following NIH, state, and local guidelines.
Statistical analysis
Statistical analysis was performed with Jmp 5.1 (SAS Institute Inc, Cary, NC). Data sets
were analyzed using one- or two-way analysis of variance (ANOVA), followed by Tukey’s
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HSD test for multiple comparisons. p-values less than 0.05 were considered statistically
significant. All values are reported as mean ± s.e.m.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Synthesis of interbilayer-crosslinked multilamellar vesicles (ICMVs)
a, Schematic illustration of ICMV synthesis and cryoelectron microscope images: (i)
Anionic, maleimide-functionalized liposomes are prepared from dried lipid films, (ii)
divalent cations are added to induce fusion of liposomes and the formation of MLVs, (iii)
membrane-permeable dithiols are added, which crosslink maleimide-lipids on apposed lipid
bilayers in the vesicle walls, and (iv) the resulting lipid particles are PEGylated with thiol-
terminated PEG. Cryo-EM images from each step of the synthesis show (i) initial liposomes,
(ii) MLVs, and (iii) ICMVs with thick lipid walls. Scale bars = 100 nm. Right-hand image
of (iii) shows a zoomed image of an ICMV wall, where stacked bilayers are resolved as
electron-dense striations; scale bar = 20 nm. b, ICMV particle size histogram measured by
dynamic light scattering. c, d, Histograms of ICMV properties from cryo-EM images show
(c) the number of lipid bilayers per particle, and (d) the ratio of particle radius to lipid wall
thickness. (n = 165 particles analyzed).
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Figure 2. Protein encapsulation and release from ICMVs
a, Encapsulation efficiency of the globular proteins SIV-gag, FLT-3L, or OVA in lipid
vesicles collected at each step of ICMV synthesis. b, c, Comparison of OVA encapsulation
efficiency (b), and total protein loading per particle mass (c) in ICMVs vs. dehydration-
rehydration vesicles (DRVs) or PLGA nanoparticles. d, Kinetics of OVA release from
simple liposomes, MLVs, or ICMVs (all with base lipid composition 4:5:1
DOPC:MPB:DOPG) incubated in RPMI medium with 10% serum at 37°C measured over
30 days in vitro. Also shown for comparison are release kinetics for liposomes stabilized
with cholesterol and PEG-lipid (38:57:5 DOPC:chol:PEG-DOPE). e, Release of OVA from
ICMVs was measured in buffers simulating different aspects of the endolysomal
environment: reducing buffer, 100 mM β-mercaptoethanol (β-ME) in PBS; acidic buffer, 50
mM sodium citrate pH 5.0; lipase-containing buffer, 500 ng/mL lipase A in PBS. Data
represent the mean ± s.e.m of at least three experiments with n = 3.
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Figure 3. In vitro stimulation of immune responses by ICMVs supplemented with the TLR
agonist MPLA
a, Flow cytometry analysis of expression of the cell surface costimulatory markers CD40,
CD80, and CD86 on splenic dendritic cells (DCs) after 18 hr incubation with 0.7 µg/mL
soluble OVA, equivalent doses of OVA loaded in ICMVs, or ICMVs loaded with an
irrelevant protein (vivax malaria protein, VMP), in the presence or absence of 0.1 µg/mL
MPLA. b, Splenic DCs were incubated for 18 hr with 10 µg/mL SIINFEKL peptide
(OVA257–264), 5.0 µg/mL soluble OVA, equivalent doses of OVA loaded in ICMVs, or
VMP-loaded ICMVs in the presence or absence of 0.05 µg/mL MPLA, and the extent of
cross-presentation of OVA was assessed by flow cytometry analysis of cells stained with the
25-D1.16 mAb that recognizes SIINFEKL complexed with H-2Kb. c, 5-(6)-
carboxyfluorescein diacetate succinimidyl diester (CFSE)-labeled OVA-specific naïve OT-I
CD8+ T-cells were co-cultured with syngeneic splenic DCs pulsed with soluble 0.7 µg/mL
OVA mixed with 0.1 µg/mL MPLA, or equivalent doses of OVA-loaded ICMVs mixed with
MPLA. Empty ICMVs without antigen or ICMVs loaded with the irrelevant antigen VMP
were included as negative controls. Proliferation of CD8+ T-cells was assessed on day 3 by
flow cytometry analysis of the dilution of CFSE in the OT-I CD8+ T-cells; shown are
histograms of CFSE fluorescence. Gates on each histogram indicate the percentage of
divided cells in each sample. Data represent the mean ± s.e.m of at least three experiments
with n = 3–4.
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Figure 4. In vivo immunization with ICMVs vs. soluble antigen or antigen encapsulated in non-
crosslinked vesicles
a, b, C57Bl/6 mice were immunized s.c. with a single injection of 10 µg OVA delivered in
soluble, liposomal, MLV, or ICMV formulations, each mixed with 0.1 µg of MPLA. a, The
percentage of antigen-specific CD8+ T-cells was determined by flow cytometry analysis of
peripheral blood mononuclear cells (PBMCs) 7 days post immunization with fluorescent
OVA peptide-MHC tetramers. b, Sera from the immunized mice were analyzed by ELISA
21 days post immunization for OVA-specific IgG. c, d, C57Bl/6 mice were injected with 10
µg of fluorophore-conjugated OVA mixed with 0.1 µg of MPLA as a soluble, liposomal, or
ICMV formulation, and the draining inguinal lymph node (dLN) cells that internalized OVA
were assessed on day 2. c, Shown are percentages of DCs (CD11c+), macrophages (F4/80+),
B cells (B220+), and plasmacytoid DCs (CD11c+B220+) positive for OVA uptake, and d,
the mean fluorescence intensity (MFI) of OVA+ populations. e, f, C57Bl/6 mice were
injected with 10 µg of OVA mixed with 0.1 µg of MPLA as a soluble, liposomal, or ICMV
formulation, and 2 d later, DCs isolated from draining inguinal LNs were analyzed by flow
cytometry to assess DC activation and antigen cross-presentation. e, Overlaid histograms
show costimulatory markers (CD40 and CD86) and MHC-II expression in DCs. f, The left
panel shows overlaid histograms of inguinal LN DCs stained for SIINFEKL-Kb+ complexes,
and mean MFI levels are shown on the right panel. Data represent mean ± s.e.m of 2–3
independent experiments conducted with n = 3–4. *, p < 0.05 and **, p < 0.01, analyzed by
one-way ANOVA, followed by Tukey’s HSD.
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Figure 5. ICMVs carrying antigen in the aqueous core and MPLA embedded in the vesicle walls
elicit potent antibody and CD8+ T-cell responses
a, Schematic illustration of the vaccine groups: soluble OVA mixed with MPLA (MPLA),
OVA-loaded ICMVs with MPLA only on the external surface (ext-MPLA ICMVs), or
OVA-loaded ICMVs with MPLA throughout the lipid multilayers (int-MPLA ICMVs). b–g,
C57Bl/6 mice were immunized on days 0, 21, and 35 at tail base s.c. with 10 µg OVA and
either 0.1 µg or 1.0 µg of MPLA formulated either as MPLA, ext-MPLA ICMVs, or int-
MPLA ICMVs. b, ELISA analysis of total OVA-specific IgG in sera. c, Frequency of OVA-
specific T-cells in peripheral blood assessed over time via flow cytometry analysis of
tetramer+CD8+ T-cells for vaccinations with 10 µg OVA and 0.1 µg MPLA. Response to
vaccinations with soluble OVA + 1 µg MPLA (MPLA 10X) also shown for comparison.
Shown are representative flow cytometry scatter plots from individual mice at d41 and mean
tetramer+ values from groups of mice vs. time. d, Analysis of T-cell effector/effector
memory/central memory phenotypes in peripheral blood by CD44/CD62L staining on
tetramer+ cells from peripheral blood on d41. Shown are representative cytometry plots from
individual mice and mean percentages of tet+CD44+CD62L+ cells among CD8+ T-cells at
d41. e, Functionality of antigen-specific CD8+ T-cells was assayed on d49 with intracellular
IFN-γ staining after ex vivo restimulation of PBMCs with OVA peptide in vitro.
Representative flow cytometry histograms of IFN-γ+CD8+ T-cells from individual mice and
mean results from groups are shown. Data represent the mean ± s.e.m of two independent
experiments conducted with n = 3. c, *, p < 0.05 compared to sol OVA + MPLA and #, p <
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0.05 compared to ext-MPLA ICMVs. d, e, *, p < 0.05 and **, p < 0.01, analyzed by two-
way ANOVA, followed by Tukey’s HSD.
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Table 2
ICMV particle yield with varying synthesis conditions
Entry Lipid composition (molar ratio)a Cationb Crosslinkerc Yield %d
1 DOPC/DOPG/MPB(40:10:50) MgCl2 DTT 45
2 DOPC/DOPG/MPB(40:10:50) CaCl2 DTT 50
3 DOPC/DOPG/MPB(40:10:50) 20 mM NaCl DTT 0
4 DOPC/DOPG/MPB(40:10:50) MgCl2 - 0
5 DOPC/DOPG/MPB(40:10:50) - DTT 0
6 DOPC/DOPG/MPB(40:10:50) - 15 mM DTT 4
7 DOPC/DOPG/MPB(60:15:25) MgCl2 DTT 15
8 DOPC/DOPG/MPB(72:18:10) MgCl2 DTT 0
9 DOPC/DOPG(80:20) MgCl2 DTT 0
10 DOPC/DOPG/MPB(40:10:50) MgCl2 DPDPBe 48
11 DOPC/DOPG/MPB(40:10:50) MgCl2 (PEG)-SH2f 3
ahydrated with 10 mM bis-tris propane at pH 7.0;
b
at 10 mM unless noted otherwise;
c
at 1.15 mM unless noted otherwise
dpercentage of lipid mass recovered after synthesis and centrifugation at 14,000 × g for 4 min
e1,4-Di-[3´-(2´-pyridyldithio)-propionamido]butane (MW 482);
f
MW 2000
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